ABT:NYE-Abbott Laboratories (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 126.05

Change

-0.52 (-0.41)%

Market Cap

USD 226.62B

Volume

3.91M

Avg Analyst Target

USD 140.62 (+11.56%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Abbott Laboratories (ABT) Stock Analysis:
Based on the Abbott Laboratories stock forecasts from 10 analysts, the average analyst target price for Abbott Laboratories is USD 140.62 over the next 12 months. Abbott Laboratories’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Abbott Laboratories is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Abbott Laboratories’s stock price was USD 126.05. Abbott Laboratories’s stock price has changed by -7.67% over the past week, -11.06% over the past month and +11.66% over the last year.

About

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment prov ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MDT Medtronic plc

+0.27 (+0.25%)

USD145.95B 31.30 19.83
SYK Stryker Corporation

-2.18 (-0.84%)

USD100.58B 43.25 29.98
EW Edwards Lifesciences Corporati..

+0.33 (+0.28%)

USD72.32B 49.82 56.15
BSX Boston Scientific Corporation

-0.17 (-0.38%)

USD63.93B 106.27 24.46
PHG Koninklijke Philips N.V

+0.35 (+1.04%)

USD30.34B 14.16 30.12
ZBH Zimmer Biomet Holdings Inc

-3.08 (-2.44%)

USD26.61B 49.18 16.05
STE STERIS plc

+1.48 (+0.64%)

USD23.04B 83.77 36.60
BIO-B Bio-Rad Laboratories Inc

+4.34 (+0.72%)

USD18.78B 2.83 2.44
BIO Bio-Rad Laboratories Inc

-1.36 (-0.23%)

USD18.78B 4.99 2.44
SNN Smith & Nephew plc

+0.49 (+1.45%)

USD15.20B 26.18 13.97

ETFs Containing ABT

Symbol Name Weight Mer Price(Change) Market Cap
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 2.19 %

+0.09 (+0.48%)

USD0.11B
XUHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

+0.11 (+0.20%)

USD0.70B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

-0.25 (-0.03%)

USD1.69B
ISDU:LSE iShares II Public Limited.. 0.00 % 0.50 %

+0.04 (+0.07%)

USD0.19B
ISDW:LSE iShares II Public Limited.. 0.00 % 0.60 %

+0.13 (+0.30%)

USD0.36B
ISUS:LSE iShares II Public Limited.. 0.00 % 0.50 %

-9.10 (-0.20%)

USD0.19B
ISWD:LSE iShares II Public Limited.. 0.00 % 0.60 %

-1.00 (-0.03%)

USD0.36B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.04 (+0.35%)

USD2.06B
OPEN:LSE iShares Thomson Reuters I.. 0.00 % 0.25 %

-0.04 (-0.53%)

USD0.04B
SXLV:LSE SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

+0.16 (+0.42%)

USD0.30B
WHEA:LSE SPDR MSCI World Health Ca.. 0.00 % 0.30 %

+0.01 (+0.01%)

USD0.48B
XDWH:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

+0.11 (+0.23%)

USD1.91B
XSHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

-3.94 (-0.10%)

USD0.70B
OPEN:F iShares VI Public Limited.. 0.00 % 0.25 %

-0.08 (-1.24%)

USD5.05M
DRDR:LSE iShares IV Public Limited.. 0.00 % 0.40 %

-2.38 (-0.39%)

USD1.91B
QDVG:F iShares V Public Limited .. 0.00 % 0.15 %

-0.05 (-0.54%)

USD2.06B
XDWH:F Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

-0.47 (-1.08%)

USD1.10B
ZPDH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

-0.18 (-0.52%)

USD0.30B
QDVG:XETRA iShares V Public Limited .. 0.00 % 0.15 %

+0.01 (+0.16%)

USD2.06B
XDWH:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

+0.04 (+0.08%)

USD1.91B
XUHC:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

+0.06 (+0.13%)

USD0.70B
ZPDH:XETRA SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

+0.07 (+0.19%)

USD0.30B
HIG-U:CA Brompton Global Healthcar.. 0.00 % 0.75 %

N/A

USD0.05B
LONG:CA CI Global Longevity Econo.. 0.00 % 0.96 %

N/A

USD0.07B
ANEW ProShares Trust - ProShar.. 0.00 % 0.45 %

-0.19 (-0.46%)

N/A
CBUF:XETRA iShares V Public Limited .. 0.00 % 0.25 %

N/A

USD0.44B
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

-0.01 (-0.12%)

N/A
HEAL:LSE iShares IV Public Limited.. 0.00 % 0.40 %

-0.01 (-0.15%)

USD1.91B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.74 %

N/A

N/A
CURE Direxion Shares ETF Trust.. 0.00 % 1.01 %

-1.55 (-1.30%)

USD0.29B
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

-1.03 (-1.07%)

USD0.18B
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

-0.28 (-0.44%)

USD3.03B
FTCS First Trust Capital Stren.. 0.00 % 0.56 %

-0.30 (-0.38%)

USD9.49B
FUD:CA First Trust Value Line Di.. 0.00 % 0.04 %

N/A

USD8.98M
IHI iShares U.S. Medical Devi.. 0.00 % 0.42 %

-0.01 (-0.02%)

USD9.03B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

-0.24 (-0.28%)

USD3.70B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

-0.98 (-0.35%)

USD3.33B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

-0.26 (-0.54%)

USD0.05B
MGV Vanguard World Fund - Van.. 0.00 % 0.07 %

-0.92 (-0.86%)

USD4.52B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.64 (-0.82%)

USD0.44B
QDEF FlexShares Quality Divide.. 0.00 % 0.37 %

-0.46 (-0.81%)

USD0.46B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.12 (+0.90%)

USD1.55M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.12 (+0.90%)

USD1.55M
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

-1.05 (-0.43%)

USD19.89B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

N/A

N/A
VIG Vanguard Specialized Fund.. 0.00 % 0.06 %

-1.02 (-0.62%)

USD76.58B
VTV Vanguard Value Index Fund.. 0.00 % 0.04 %

-1.30 (-0.88%)

USD125.77B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

-0.19 (-0.29%)

USD0.52B
XHE SPDR Series Trust - SPDR .. 0.00 % 0.35 %

-0.99 (-0.93%)

USD0.69B
XLV Health Care Select Sector.. 0.00 % 0.12 %

-0.54 (-0.41%)

USD35.80B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

-0.02 (-0.23%)

USD0.33B
MIVG:CA Mackenzie Ivy Global Equi.. 0.00 % 0.84 %

N/A

USD0.03B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.45 %

-0.13 (-0.58%)

USD0.01B
ACT Enact Holdings Inc. Commo.. 0.00 % 0.99 %

-0.09 (-0.41%)

USD3.64B
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.72 %

-0.05 (-0.37%)

USD0.05B
RWDC Direxion MSCI Defensives .. 0.00 % 0.46 %

N/A

USD7.11M
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.06B
FUD-A:CA First Trust Value Line Di.. 0.00 % 0.04 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.44% 31% F 14% F
Dividend Return 0.33% 100% A+ 19% F
Total Return -10.10% 34% F 14% F
Trailing 12 Months  
Capital Gain 11.66% 84% B 63% D
Dividend Return 1.61% 63% D 31% F
Total Return 13.27% 84% B 61% D-
Trailing 5 Years  
Capital Gain 211.54% 78% C+ 94% A
Dividend Return 17.07% 100% A+ 64% D
Total Return 228.61% 89% B+ 94% A
Average Annual (5 Year Horizon)  
Capital Gain 26.11% 52% F 85% B
Dividend Return 1.89% 63% D 45% F
Total Return 28.00% 60% D- 85% B
Risk Return Profile  
Volatility (Standard Deviation) 11.09% 96% A 79% C+
Risk Adjusted Return 252.51% 96% A 100% A+
Market Capitalization 226.62B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.80 71% C- 24% F
Price/Book Ratio 6.90 25% F 14% F
Price / Cash Flow Ratio 28.68 46% F 14% F
EV/EBITDA 19.97 65% D 27% F
Management Effectiveness  
Return on Equity 21.86% 71% C- 66% D
Return on Invested Capital 9.65% 97% A+ 74% C
Return on Assets 7.74% 93% A 86% B
Debt to Equity Ratio 56.51% 38% F 58% F
Technical Ratios  
Short Ratio 1.54 89% B+ 59% F
Short Percent 0.49% 93% A 85% B
Beta 0.70 81% B- 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector